SG11201403891SA - Purification of flaviviruses - Google Patents

Purification of flaviviruses

Info

Publication number
SG11201403891SA
SG11201403891SA SG11201403891SA SG11201403891SA SG11201403891SA SG 11201403891S A SG11201403891S A SG 11201403891SA SG 11201403891S A SG11201403891S A SG 11201403891SA SG 11201403891S A SG11201403891S A SG 11201403891SA SG 11201403891S A SG11201403891S A SG 11201403891SA
Authority
SG
Singapore
Prior art keywords
flaviviruses
purification
Prior art date
Application number
SG11201403891SA
Other languages
English (en)
Inventor
Sophia Mundle
Stephen Anderson
Original Assignee
Sanofi Pasteur Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Llc filed Critical Sanofi Pasteur Biologics Llc
Publication of SG11201403891SA publication Critical patent/SG11201403891SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201403891SA 2012-01-09 2013-01-08 Purification of flaviviruses SG11201403891SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261584461P 2012-01-09 2012-01-09
PCT/US2013/020686 WO2013106337A1 (fr) 2012-01-09 2013-01-08 Purification des flavivirus

Publications (1)

Publication Number Publication Date
SG11201403891SA true SG11201403891SA (en) 2014-08-28

Family

ID=48781838

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201510800PA SG10201510800PA (en) 2012-01-09 2013-01-08 Purification of flaviviruses
SG11201403891SA SG11201403891SA (en) 2012-01-09 2013-01-08 Purification of flaviviruses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201510800PA SG10201510800PA (en) 2012-01-09 2013-01-08 Purification of flaviviruses

Country Status (6)

Country Link
US (1) US20150030565A1 (fr)
EP (1) EP2802650A4 (fr)
AU (1) AU2013208187B2 (fr)
CA (1) CA2896931A1 (fr)
SG (2) SG10201510800PA (fr)
WO (1) WO2013106337A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195452A2 (fr) 2014-06-16 2015-12-23 Emd Millipore Corporation Systèmes et procédés de filtration à simple passage
WO2015195453A2 (fr) 2014-06-16 2015-12-23 Emd Millipore Corporation Procédés pour augmenter la capacité de processus à écoulement continu
KR102199262B1 (ko) 2014-06-25 2021-01-06 이엠디 밀리포어 코포레이션 밀집한 나권형 필터 엘리먼트, 모듈 및 시스템
SG11201508664VA (en) 2014-08-29 2016-03-30 Emd Millipore Corp Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate
CN108325391B (zh) 2014-08-29 2021-05-18 Emd 密理博公司 过滤液体进料的方法
WO2017053239A1 (fr) * 2015-09-22 2017-03-30 Sanofi Pasteur Biologics, Llc Purification du virus respiratoire syncytial
JP7261239B2 (ja) * 2017-10-16 2023-04-19 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生組換えフラビウイルスなどから成る安定したワクチン組成物およびその調製方法
CA3104392A1 (fr) * 2018-07-04 2020-01-09 Probiogen Ag Procede de purification d'un virus enveloppe
WO2021174059A1 (fr) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Procédé d'élimination d'adn de cellule hôte à partir d'une préparation virale
GB202215814D0 (en) * 2022-10-26 2022-12-07 Cytiva Bioprocess R & D Ab A chromatography device, system, and use thereof for analytic separation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889632A (en) 1987-12-10 1989-12-26 Ceskoslovenska Akademie Ved Macroporous polymeric membranes for the separation of polymers and a method of their application
DE69520586T2 (de) 1994-08-23 2001-11-15 Bia Separations D.O.O., Ljubljana Verfahren und vorrichtung zur schnellen trennung und/oder umwandlung von substraten
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US6207439B1 (en) * 1997-03-25 2001-03-27 Center For Disease Control Purification of Japanese encephalitis virus
CZ302614B6 (cs) 1998-02-27 2011-08-03 Bia Separations D. O. O. Porézní samonosná polymerní struktura, výrobek s touto strukturou a zpusob její výroby
US6664305B2 (en) 2000-06-27 2003-12-16 Bia Separations D.O.O. Chromatography material and a process of manufacturing that material
WO2003101397A2 (fr) 2002-05-31 2003-12-11 Acambis, Inc. Vaccins tetravalents contre la dengue
AU2006233800B2 (en) * 2005-04-11 2011-07-07 Crucell Holland B.V. Virus purification using ultrafiltration
BRPI0609949A2 (pt) * 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus
WO2006122964A1 (fr) 2005-05-19 2006-11-23 Crucell Holland B.V. Methodes de production d'un vaccin contre le virus du nil occidental entier inactive
JP5538729B2 (ja) * 2006-02-27 2014-07-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 偽感染性フラビウイルスおよびそれらの使用
EP1878791A1 (fr) * 2006-07-11 2008-01-16 Bia Separations D.O.O. Procédé de purification de virus de la grippe
EP2043681B1 (fr) 2006-07-14 2015-10-07 Sanofi Pasteur Biologics, LLC Construction de vaccins antiviraux de recombinaison par insertion directe a mediation par transposon de determinants immunologiques etrangers dans des proteines de virus vecteur
EP2121010A4 (fr) * 2007-01-31 2011-02-16 Sanofi Pasteur Biologics Co Vecteurs de flavivirus bicistroniques recombinants
CN102202687B (zh) * 2008-03-14 2015-07-29 赛诺菲巴斯德生物制剂有限责任公司 复制缺陷型黄病毒疫苗和疫苗载体
US20120128713A1 (en) 2009-03-16 2012-05-24 Sanofi Pasteur Limited Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus
US20110142863A1 (en) * 2009-12-16 2011-06-16 Millipore Corporation Flow through purification processes for large biomolecules

Also Published As

Publication number Publication date
AU2013208187A1 (en) 2014-07-24
SG10201510800PA (en) 2016-01-28
EP2802650A4 (fr) 2015-09-30
CA2896931A1 (fr) 2013-07-18
WO2013106337A1 (fr) 2013-07-18
EP2802650A1 (fr) 2014-11-19
AU2013208187B2 (en) 2018-07-12
US20150030565A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
IL287057A (en) Purified iduronate-2-sulfatase
EP2826473A4 (fr) Nouvelle utilisation du patchoulol
SG11201403891SA (en) Purification of flaviviruses
ZA201406082B (en) Use of ccr3-inhibitors
EP2917314A4 (fr) Composition d'oligomère
IL263162B (en) Purification of cystathionine beta-synthase
IL236312A0 (en) Preparation of 18f-flucyclobin
EP2881113A4 (fr) Nouvelle application de la pogostone
HK1202053A1 (en) Treatment of liver conditions
SG11201406800UA (en) Purification of air
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
EP2892529A4 (fr) Utilisations de (-)-perhexiline
SG11201504201RA (en) Purification of x-ray contrast agents
GB201207907D0 (en) Treatment of depression
IL233740A0 (en) Treatment of liver diseases
TWM433525U (en) Structure of calorifier